Does North Dakota Medicaid Cover Wegovy or Zepbound?
North Dakota (ND) GLP-1 access depends on three state-specific policy questions before it ever gets to pricing: does North Dakota Medicaid cover weight-loss GLP-1s, has North Dakota expanded Medicaid under the ACA, and does the state employee health plan cover them. Answering those first tells you whether you're likely working with insurance or planning for cash-pay.
North Dakota Medicaid GLP-1 coverage: what the state's own documents say
North Dakota Medicaid pharmacy (carved out of managed care since January 1, 2020) covers none of Wegovy, Zepbound or Saxenda for obesity: Wegovy is non-preferred with prior authorization for cardiovascular risk only (age 55 to under 75, no diabetes, BMI 27 to under 35, prior heart attack or stroke plus peripheral artery disease) and Zepbound only for sleep apnea, but the program does cover non-GLP-1 obesity drugs (phentermine, bupropion, naltrexone, topiramate) without prior authorization.
Checked September 20, 2026 against: ndmedicaid.acentra.com, hhs.nd.gov, hhs.nd.gov.
North Dakota state employee health plan: what the plan's own documents say
North Dakota's NDPERS Dakota Plan formulary (dated July 22, 2026) has no anti-obesity category and lists no Wegovy, Zepbound, Saxenda, Foundayo, Contrave, Qsymia, orlistat or phentermine; it lists only diabetes GLP-1s with prior authorization and quantity limits. The certificate excludes medications not on the formulary and appetite suppressants. No sentence naming GLP-1s for weight loss was found, so this classification rests on the formulary omission plus those general exclusions.
Checked September 20, 2026 against: sanfordhealthplan.com, ndpers.nd.gov, ndpers.nd.gov.
Notable insurers active in North Dakota (not independently verified): Blue Cross Blue Shield of North Dakota, Sanford Health Plan, Medica.
Why GLP-1 coverage varies this much by state
Medicaid is a state-federal partnership, not a single national program. Each state Medicaid agency sets its own preferred drug list (PDL) and prior-authorization criteria within federal minimum requirements. Weight-loss drugs are not a federally mandated Medicaid benefit, so states choose independently whether to cover them - which is why only 10 of 50 states currently do (North Dakota is not one of them).
State employee health plans are a useful bellwether. These plans cover hundreds of thousands of state workers and negotiate directly with pharmacy benefit managers, so their coverage decisions often signal where commercial insurers in that state are heading. North Carolina's State Health Plan, for example, ended coverage of weight-loss GLP-1s on April 1, 2024, after its board voted 4-3 to cut it citing the drugs' high cost - a case that other states and large employers have watched closely.
Medicaid expansion status shapes who even has coverage to begin with. States that haven't adopted ACA Medicaid expansion have narrower Medicaid eligibility overall, which - combined with the weight-loss GLP-1 exclusion most states apply regardless of expansion status - pushes a larger share of residents in those states toward commercial insurance, telehealth, or manufacturer self-pay as their only realistic path.
National reference pricing (same nationwide - your actual cost depends on your plan)
These prices are the same across all 50 states because manufacturer list prices, self-pay programs, and telehealth pricing don't vary by state - only insurance coverage and copay do, which is why the North Dakota-specific policy facts above matter more than the table below for predicting your actual cost.
| Drug | Covered by insurance | Manufacturer self-pay | Telehealth | Cash retail |
|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $1,349 |
| Ozempic 11.6% weight loss | $63 | - | $399 | $1,028 |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 | $449 | $1,349 |
| Zepbound 22.5% weight loss | $88 | $299 | $499 | $1,059 |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $1,069 |
| Saxenda 8.4% weight loss | $63 | - | $399 | $1,349 |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 | - | $1,099 |
| CagriSema 20.4% weight loss | $88 | $599 | - | $1,499 |
Cheapest cash-pay GLP-1 paths for North Dakota residents
Manufacturer direct prices (LillyDirect, NovoCare) are usually cheapest. Updated May 2026.
| Drug | Insurance | Mfr direct | Telehealth (brand) | Telehealth (compd) | Cash retail | Get it |
|---|---|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $249 cheapest | $1,349 | Get →ad |
| Ozempic 11.6% weight loss | $63 | - | $399 | $199 cheapest | $1,028 | Get →ad |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 cheapest | $449 | - | $1,349 | Get →ad |
| Zepbound 22.5% weight loss | $88 | $299 cheapest | $499 | $299 cheapest | $1,059 | Get →ad |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $299 cheapest | $1,069 | Get →ad |
| Saxenda 8.4% weight loss | $63 | - | $399 cheapest | - | $1,349 | Get →ad |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 cheapest | - | - | $1,099 | Get →ad |
Frequently asked questions
Does North Dakota Medicaid cover Wegovy or Zepbound for weight loss?
No. North Dakota Medicaid pharmacy (carved out of managed care since January 1, 2020) covers none of Wegovy, Zepbound or Saxenda for obesity: Wegovy is non-preferred with prior authorization for cardiovascular risk only (age 55 to under 75, no diabetes, BMI 27 to under 35, prior heart attack or stroke plus peripheral artery disease) and Zepbound only for sleep apnea, but the program does cover non-GLP-1 obesity drugs (phentermine, bupropion, naltrexone, topiramate) without prior authorization. This was checked against North Dakota's own documents on September 20, 2026; coverage rules change often, so confirm with your plan before relying on it. Coverage for type 2 diabetes (Ozempic, Mounjaro) is a separate question. Medicare's GLP-1 Bridge, which started July 1, 2026, works separately from Medicaid and applies in every state.
Has North Dakota expanded Medicaid under the ACA?
Yes - North Dakota has adopted Medicaid expansion, which broadens who qualifies for Medicaid coverage generally, though it does not by itself guarantee GLP-1 weight-loss coverage (see above).
Does the North Dakota state employee health plan cover Wegovy or Zepbound?
No. North Dakota's NDPERS Dakota Plan formulary (dated July 22, 2026) has no anti-obesity category and lists no Wegovy, Zepbound, Saxenda, Foundayo, Contrave, Qsymia, orlistat or phentermine; it lists only diabetes GLP-1s with prior authorization and quantity limits. The certificate excludes medications not on the formulary and appetite suppressants. No sentence naming GLP-1s for weight loss was found, so this classification rests on the formulary omission plus those general exclusions. This was checked against North Dakota's own plan documents on September 20, 2026; plan terms are reset each plan year, so confirm with your plan before relying on it.